Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Eli Lilly stock hits all-time high as healthcare shares rise

BUZZ - Eli Lilly stock hits all-time high as healthcare shares rise

路透社路透社2026/10/20 14:31
Show original

- ** Shares of the world’s largest pharmaceutical company Eli Lilly (LLY.N) rose 5.45%, reaching a record high of $1,307.91

** The previous 52-week high for the stock was $1,292.65

** According to data from the London Stock Exchange Group (LSEG), Wall Street holds an overall optimistic view on this trillion-dollar market cap stock, with 29 analysts rating it as “Buy” or “Strong Buy,” 3 rating it “Hold,” and 1 rating it “Sell.” The median target price is $1,380.50

** LLY has expanded its drug research pipeline through a series of acquisitions and licensing agreements, using strong cash flow from its diabetes and weight loss drugs to drive broader M&A activity

** Other major pharmaceutical companies, including Amgen (AMGN.O), Pfizer (PFE.N), Johnson & Johnson (JNJ.N), and AbbVie (ABBV.N), also saw gains in early trading; the broader S&P 500 Health Care Index .SPXHC hit a record high

** Including today’s gains, LLY stock has climbed about 21% so far this year


(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may be inaccurate or lack the necessary context, Reuters does not guarantee the accuracy of these automated translations, which are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs

Audi plans to invest 4 billion dollars to build a factory in the United States, with an annual production capacity of 200,000 SUVs, creating 4,500 jobs. The German labor union criticized the CEO's supportive attitude as "puzzling," and the final decision will be made by the Volkswagen supervisory board.

智通财经•2026/10/26 03:11
Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs